Astex
  • Discover Astex
    • Our Mission & Values
    • Our Leadership Team
      • Harren Jhoti
      • David Rees
      • John Lyons
      • Chris Murray
      • Jeremy Carmichael
      • Lee Dawson
      • Tom Heightman
      • Neil Jones
      • Nicola Wallis
      • Mohammad Azab
      • Martin Buckland
      • Harold N. Keer
      • Nipun Davar
      • Yong Hao
      • Joseph Iovino
      • Samuel Jason
      • Charles LaPree
      • Shinichi Sato
      • Nancy Worrell
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Guadecitabine (SGI-110) DNMT inhibitor (Treatment Naïve AML)
      • Guadecitabine (SGI-110) DNMT inhibitor (Relapsed/Refractory AML)
      • Guadecitabine (SGI-110) DNMT inhibitor (Relapsed/Refractory MDS or CMML)
      • Guadecitabine (SGI-110) DNMT inhibitor (Solid Tumors)
      • ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
      • ASTX727 Oral DNMT inhibitor (Hematologic Malignancies)
      • ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
      • Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
      • AZD3293 (lanabecestat) Beta Secretase (BACE) inhibitor (Alzheimer’s disease)
      • AZD5363 PKB/Akt Inhibitor (Oncology)
      • JNJ42756493 (erdafitinib) FGFr inhibitor (Oncology)
      • Multiple Targets and Therapeutic Areas
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation
  • Partnering
  • Our People
    • Career Opportunities
  • Media
    • Press Releases
      • Press Releases – Archive
    • Conferences & Meetings
    • Presentations & Publications
    • Astex in the News
  • Contact
  • Search
  • Menu
You are here: Home / 2004 / SuperGen Announces FDA Acceptance of Rolling NDA Request for Dacogen™...

SuperGen Announces FDA Acceptance of Rolling NDA Request for Dacogen™

22 April 2004/in 2004, News /by webadmin

SuperGen Announces FDA Acceptance of Rolling NDA Request for Dacogen™

/wp-content/uploads/2016/11/logo.png 0 0 webadmin /wp-content/uploads/2016/11/logo.png webadmin2004-04-22 14:31:092016-11-28 14:31:31SuperGen Announces FDA Acceptance of Rolling NDA Request for Dacogen™

Copyright © Astex Pharmaceuticals
All rights reserved

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal

Member of the Otsuka Group

SuperGen (Nasdaq: SUPG) Will Webcast Its Scientific Review and Corporate Update... SuperGen Reports 2004 First Quarter Financial Results
Scroll to top
By continuing to use this website you will be agreeing to our Terms & Conditions, our Privacy Policy, and the use of cookies.continue